Gastrointestinal Cancer

项目总结(见说明)： 胃肠道(Gl)癌症计划(计划#6)是杰斐逊基梅尔癌症中心最初的计划之一，是一个多学科计划，由25名正式成员和5名准成员组成，代表杰斐逊医学院(病理学、癌症生物学、家庭医学、内科、肿瘤学、药理学、放射学、外科)、克里斯蒂娜护理健康系统(海伦·F·格雷厄姆癌症中心)和德雷克塞尔大学，其总体目标是定义 Gl恶性肿瘤的基本机制，可转化为诊断和治疗创新，用于管理患者和人群的癌症。他们的工作得到了�约770万美元的同行审查资金的支持，比上一个资助期的440万美元增加了-75%。此外，计划成员已经发表了561篇论文，与前一个资助时期相比几乎翻了一番。其中，方案内方案占17%，是以前的三倍，方案间占16%。计划成员沿着基于器官的疾病过程进行平行的努力，从发现到翻译，再到临床开发和应用。 成员使用共同和协作的实验范式，目标是(1)定义先前未被认识的基于Gl器官的肿瘤发生的分子、遗传和表观遗传学机制，(2)将已定义的机制转化为新的体外和体内工具，以改进G1恶性肿瘤的预防、早期检测、预后、预测和风险分层，(3)定义用于癌症预防、治疗和控制的分子靶向治疗方法，(4)将实验室的新发现转化为临床试验的开发，以及(5)将临床成功的诊断和治疗试验转化为以证据为基础的实践，用于跨人群的癌症预防和控制。在这种情况下，参加基于Gl癌症的临床试验的患者人数比过去的资助期增加了约15倍。成员互动，有凝聚力，在项目负责人的指导下，与癌症中心的其他研究项目协调研究计划和新的研究方向。

PROJECT SUMMARY (See Instructions): The Gastrointestinal (Gl) Cancer Program (Program #6), one of the original programs of the Kimmel Cancer Center at Jefferson, is a multidisciplinary program composed of 25 full and 5 associate members representing 8 departments within Jefferson Medical College (Pathology; Cancer Biology; Family Medicine; Internal Medicine; Medical Oncology; Pharmacology; Radiology; Surgery), the Christiana Care Health System (Helen F. Graham Cancer Center), and Drexel University, whose over-arching goal is to define fundamental mechanisms underlying Gl malignancies which can be translated into diagnostic and therapeutic innovations for managing cancer in patients and populations. Their work is supported by �~$7.7M in peer-reviewed funding, representing an increase of -75% from $4.4M during the past funding period. Also, program members have published 561 papers, representing almost a doubling compared to the previous funding period. Of those, >17% were intra-programmatic, representing a tripling of the previous rate, and >16% were inter-programmatic. Program members pursue parallel efforts organized along organ based disease processes from discovery through translation to clinical development and application. Members employ common and collaborative experimental paradigms with the goals of (1) defining previously unappreciated molecular, genetic, and epigenetic mechanisms underlying Gl organ-based tumorigenesis, (2) translating defined mechanisms into novel in vitro and in vivo tools to improve prevention, early detection, prognosis, prediction, and risk-stratification in Gl malignancies, (3) defining molecularly targeted therapeutic approaches for cancer prevention, treatment, and control, (4) advancing novel laboratory discoveries into development for clinical trials, and (5) advancing clinically successful diagnostic and therapeutic trials into evidence-based practice for cancer prevention and control across populations. In that context, enrollment of patients in Gl cancer-based clinical trials has increased ~15-fold compared to the past funding period. Members are interactive and cohesive and, under the direction of Program Leaders, coordinate research planning and new research directions with other research programs in the Cancer Center.